The increasing use of liquid biopsy sampling instead of tissue sampling may reduce the effect of heterogeneity of PD-L1 expression within a given tumor or between different tumors, thus enhancing the detection reliability of PD-L1 as a predictive biomarker in response to PD-1/PD-L1 therapy. Here, PDCD1 is linked to neoplasm.